• 1
    Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:107.
  • 2
    Potischman N, Hoover RN, Brinton LA et al. Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst 1996;88:112735.
  • 3
    Mutter GL, Lin MC, Fitzgerald JT et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000;92:92430.
  • 4
    MacDonald ND, Salvesen HB, Ryan A, Iversen OE, Akslen LA, Jacobs IJ. Frequency and prognostic impact of microsatellite instability in a large population-based study of endometrial carcinomas. Cancer Res 2000;60:17502.
  • 5
    Sasaki H, Nishii H, Takahashi H et al. Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma. Cancer Res 1993;53:190610.
  • 6
    Nakashima M, Sonoda K, Watanabe T. Inhibition of cell growth and induction of apoptosis cell death by the human tumor-associated antigen RCAS1. Nat Med 1999;5:93842.
  • 7
    Iwasaki T, Nakashima M, Watanabe T, Yamamoto S, Inoue Y, Yamanaka H. Expression and prognostic significance in lung cancer of human tumor-associated antigen RCAS1. Int J Cancer 2000;89:48893.
  • 8
    Nakakubo Y, Hida Y, Miyamoto M, Hashida H, Oshiriki T, Kato K. The prognostic significance of RCAS1 expression in squamous cell carcinoma of the oesophagus. Cancer Lett 2002;177:1015.
  • 9
    Oshiriki T, Hida Y, Miyamoto M et al. RCAS1 as a tumor progression marker: an independent negative prognostic factor in gallbladder cancer. Br J Cancer 2001;85:19227.
  • 10
    Hiraoka K, Hida Y, Miyamoto M, Oshikiri T, Suzuoki M, Nakakubo Y. High expression of tumor-associated antigen RCAS1 in pancreatic ductal adenocarcinoma is an unfavorable prognostic marker. Int J Cancer 2002;99:41823.
  • 11
    Watanabe T, Inoue S, Hioroi H et al. Isolation of estrogen-responsive genes with a CpG island library. Mol Cell Biol 1998;18:4429.
  • 12
    Jazaeri AA, Nunes KJ, Dalton MS, Xu M, Shupnik MA, Rice LW. Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression. Oncogene 2001;20:69659.
  • 13
    Izumi M, Nakanishi Y, Yoshino I et al. Expression of tumor-associated antigen RCAS1 correlates significantly with poor prognosis in nonsmall cell lung carcinoma. Cancer 2001;92:44651.
  • 14
    Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:15568.
  • 15
    Sonoda K, Kaku T, Hirakawa T et al. The clinical significance of tumor-associated antigen RCAS1 expression in the normal, hyperplastic, and malignant uterine endometrium. Gynecol Oncol 2000;79:4249.
  • 16
    Nakamura Y, Yamazaki K, Oizumi S, Nakashima M, Watanabe T. Expression of RCAS1 in human gastric carcinoma: a potential mechanism of immune escape. Cancer 2004;95:2605.
  • 17
    Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia: a long-term study of “untreated” hyperplasia in 170 patients. Cancer 1985;56:40312.
  • 18
    Sonoda K, Kaku T, Kamura T, Nakashima M, Watanabe T, Nakano H. Tumor-associated antigen 22-1-1 expression in the uterine cervical squamous neoplasias. Clin Cancer Res 1998;4:151720.
  • 19
    Saegusa M, Okayasu I. Changes in expression of estrogen receptors alpha and beta in relation to progesterone receptor and pS2 status in normal and malignant endometrium. JPN J Cancer Res 2000;91:5108.
  • 20
    Ikeda K, Sato M, Tsuchiya F, Tsuneizumi M, Emi M, Imoto I. Promoter analysis and chromosomal mapping of human EBAG9 gene. Biochem Biophys Res Commun 2000;273:65460.
  • 21
    Akahia JI, Aoki M, Suzuki T et al. Expression of EBAG/RCAS1 is associated with advanced disease in human epithelial ovarian cancer. Br J Cancer 2004;90:2197202.